{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:02:41Z","timestamp":1790402561872,"version":"4.1.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"18","funder":[{"name":"Verona Pharma","award":["9717732"],"award-info":[{"award-number":["9717732"]}]},{"name":"Verona Pharma","award":["9700558"],"award-info":[{"award-number":["9700558"]}]},{"name":"Verona Pharma","award":["20160008363"],"award-info":[{"award-number":["20160008363"]}]},{"name":"Verona Pharma","award":["20160000790"],"award-info":[{"award-number":["20160000790"]}]},{"name":"Verona Pharma","award":["20170266190"],"award-info":[{"award-number":["20170266190"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.2217\/imt-2023-0136","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:46:26Z","timestamp":1696232786000},"page":"1511-1519","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["What Role will Ensifentrine Play in the Future Treatment of Chronic Obstructive Pulmonary Disease Patients? Implications from Recent Clinical Trials"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[{"name":"Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome \u2018Tor Vergata\u00e2\u20ac\u2122, 00133, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-3799","authenticated-orcid":false,"given":"Clive","family":"Page","sequence":"additional","affiliation":[{"name":"Pulmonary Pharmacology Unit, Institute of Pharmaceutical Science, King\u2019s College London, SE1 9NH, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Diseases & Lung Function, Department of Medicine & Surgery, University of Parma, 43126, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Unit, University of Manchester & Manchester University NHS Foundation Trust, M23 9QZ, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome \u2018Tor Vergata\u00e2\u20ac\u2122, 00133, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology, Department of Experimental Medicine, University of Campania \u2018Luigi Vanvitelli\u00e2\u20ac\u2122, 80138, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.099192"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01675-2018"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000368800"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703725"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12209"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94888"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2002-0247OC"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407521200"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_69"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.4155\/ppa-2018-0030"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1661990"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S413436"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204644"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2015.03.007"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13512"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70187-5"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00324.2015"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.17925\/USRPD.2022.7.2.48"},{"key":"e_1_3_4_21_1","first-page":"A2838","article-title":"Twice-daily, nebulized ensifentrine produced significant improvement in week 12 lung function: subgroup analysis in the phase 3 trial ENHANCE-2","volume":"207","author":"Rickard K","year":"2023","unstructured":"Rickard K , RheaultT , BengtssonT. Twice-daily, nebulized ensifentrine produced significant improvement in week 12 lung function: subgroup analysis in the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A2838 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_22_1","first-page":"A2839","article-title":"Ensifentrine reduced healthcare resource utilization in subjects with COPD: results from ENHANCE-2, a phase 3 trial of ensifentrine, a dual PDE3\/4 inhibitor","volume":"207","author":"Barjaktarevic IZ","year":"2023","unstructured":"Barjaktarevic IZ , RheaultT , BengtssonT , RickardK. Ensifentrine reduced healthcare resource utilization in subjects with COPD: results from ENHANCE-2, a phase 3 trial of ensifentrine, a dual PDE3\/4 inhibitor. Am. J. Respir. Crit. Care Med.207, A2839 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_23_1","first-page":"A4998","article-title":"Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2","volume":"207","author":"Anzueto A","year":"2023","unstructured":"Anzueto A , RheaultT , BengtssonT , RickardK. Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A4998 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_24_1","first-page":"A4999","article-title":"Ensifentrine, a dual inhibitor of PDE3 and PDE4, reduces the risk of exacerbation regardless of background medication use: a sub-group analysis of ENHANCE-2, a phase 3 trial","volume":"207","author":"Ferguson GT","year":"2023","unstructured":"Ferguson GT , RheaultT , BengtssonT , RickardK. Ensifentrine, a dual inhibitor of PDE3 and PDE4, reduces the risk of exacerbation regardless of background medication use: a sub-group analysis of ENHANCE-2, a phase 3 trial. Am. J. Respir. Crit. Care Med.207, A4999 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_25_1","first-page":"A5000","article-title":"Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, in moderate and severe COPD: symptoms, quality of life and health status from the phase 3 trial ENHANCE-2","volume":"207","author":"Rheault T","year":"2023","unstructured":"Rheault T , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, in moderate and severe COPD: symptoms, quality of life and health status from the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A5000 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_26_1","first-page":"A5003","article-title":"Safety results from dual PDE3\/4 inhibitor ensifentrine: gastrointestinal and cardiovascular safety from a 24-week phase 3 trial, ENHANCE-2","volume":"207","author":"Siler TM","year":"2023","unstructured":"Siler TM , RickardK , BengtssonT , RheaultT. Safety results from dual PDE3\/4 inhibitor ensifentrine: gastrointestinal and cardiovascular safety from a 24-week phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med.207, A5003 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_27_1","first-page":"A5004","article-title":"Twice-daily, nebulized ensifentrine significantly improves lung function: sub-group analysis in the phase 3 trial, ENHANCE-1","volume":"207","author":"Siler TM","year":"2023","unstructured":"Siler TM , RheaultT , BengtssonT , RickardK. Twice-daily, nebulized ensifentrine significantly improves lung function: sub-group analysis in the phase 3 trial, ENHANCE-1. Am. J. Respir. Crit. Care Med.207, A5004 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_28_1","first-page":"A5006","article-title":"Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in the ENHANCE-1 phase 3 trial of ensifentrine in COPD","volume":"207","author":"Sciurba F","year":"2023","unstructured":"Sciurba F , WiseR , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in the ENHANCE-1 phase 3 trial of ensifentrine in COPD. Am. J. Respir. Crit. Care Med.207, A5006 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_29_1","first-page":"A5007","article-title":"Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly improves COPD symptoms and quality of life in the phase 3 ENHANCE-1 trial","volume":"207","author":"Sciurba F","year":"2023","unstructured":"Sciurba F , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly improves COPD symptoms and quality of life in the phase 3 ENHANCE-1 trial. Am. J. Respir. Crit. Care Med.207, A5007 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_30_1","first-page":"A5008","article-title":"Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly reduces annualized exacerbations and delays the time to first exacerbation in COPD: pooled sub-group analyses of ENHANCE-1 and ENHANCE-2 phase 3 trials","volume":"207","author":"Barjaktarevic IZ","year":"2023","unstructured":"Barjaktarevic IZ , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly reduces annualized exacerbations and delays the time to first exacerbation in COPD: pooled sub-group analyses of ENHANCE-1 and ENHANCE-2 phase 3 trials. Am. J. Respir. Crit. Care Med.207, A5008 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_31_1","first-page":"A5005","article-title":"Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in patients with COPD: results from replicate phase 3 trials","volume":"207","author":"Sciurba F","year":"2023","unstructured":"Sciurba F , AnzuetoA , RheaultT , BengtssonT , RickardK. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in patients with COPD: results from replicate phase 3 trials. Am. J. Respir. Crit. Care Med.207, A5005 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-0944OC"},{"key":"e_1_3_4_33_1","unstructured":"Jensen B . Verona Pharma: Targeting the large COPD market (2023). https:\/\/seekingalpha.com\/article\/4625531-verona-pharma-targeting-the-large-copd-market?mailingid=32348864&messageid=must_reads&serial=32348864.3878154&utm_campaign=Must%2BReads%2Brecurring%2B2023-08-09&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01074-2018"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1307-4"},{"key":"e_1_3_4_36_1","first-page":"A4298","article-title":"Additional bronchodilation by ensifentrine, a dual PDE3\/4 inhibitor, when combined with a LAMA\/LABA in patients with moderate to severe COPD","volume":"201","author":"Rickard K","year":"2020","unstructured":"Rickard K , RheaultT , BengtssonT. Additional bronchodilation by ensifentrine, a dual PDE3\/4 inhibitor, when combined with a LAMA\/LABA in patients with moderate to severe COPD. Am. J. Respir. Crit. Care Med.201, A4298 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00239-2023"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S419056"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2076592"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S285867"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1794CI"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00039.2013"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00228013"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00324.2015"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101814"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107826"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2023-0136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:27:39Z","timestamp":1715984859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2023-0136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":44,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.2217\/imt-2023-0136"],"URL":"https:\/\/doi.org\/10.2217\/imt-2023-0136","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}